Cargando…
A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases
This study aims to determine the most efficacious dose of Botulinum neurotoxin type A (BoNT-A) in reducing sialorrhea in Asian adults with neurological diseases. A prospective, double-blind randomized controlled trial was conducted over 24 weeks. Thirty patients with significant sialorrhea were rand...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591664/ https://www.ncbi.nlm.nih.gov/pubmed/26402703 http://dx.doi.org/10.3390/toxins7093758 |
_version_ | 1782393114229473280 |
---|---|
author | Mazlan, Mazlina Rajasegaran, Shivani Engkasan, Julia Patrick Nawawi, Ouzreiah Goh, Khean-Jin Freddy, Saini Jeffery |
author_facet | Mazlan, Mazlina Rajasegaran, Shivani Engkasan, Julia Patrick Nawawi, Ouzreiah Goh, Khean-Jin Freddy, Saini Jeffery |
author_sort | Mazlan, Mazlina |
collection | PubMed |
description | This study aims to determine the most efficacious dose of Botulinum neurotoxin type A (BoNT-A) in reducing sialorrhea in Asian adults with neurological diseases. A prospective, double-blind randomized controlled trial was conducted over 24 weeks. Thirty patients with significant sialorrhea were randomly assigned to receive a BoNT-A (Dysport(®)) injection into the submandibular and the parotid glands bilaterally via an ultrasound guidance. The total dose given per patient was either BoNT-A injection of (i) 50 U; (ii) 100 U; or (iii) 200 U. The primary outcome was the amount of saliva reduction, measured by the differential weight (wet versus dry) of intraoral dental gauze at baseline and at 2, 6, 12, and 24 weeks after injection. The secondary outcome was the subjective report of drooling using the Drooling Frequency and Severity Scale (DFS). Saliva reduction was observed in response to all BoNT-A doses in 17 patients who completed the assessments. Although no statistically significant difference among the doses was found, the measured reduction was greater in groups that received higher doses (100 U and 200 U). The group receiving 200 U of Dysport(®) showed the greatest reduction of saliva until 24 weeks and reported the most significant improvement in the DFS score. |
format | Online Article Text |
id | pubmed-4591664 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-45916642015-10-05 A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases Mazlan, Mazlina Rajasegaran, Shivani Engkasan, Julia Patrick Nawawi, Ouzreiah Goh, Khean-Jin Freddy, Saini Jeffery Toxins (Basel) Article This study aims to determine the most efficacious dose of Botulinum neurotoxin type A (BoNT-A) in reducing sialorrhea in Asian adults with neurological diseases. A prospective, double-blind randomized controlled trial was conducted over 24 weeks. Thirty patients with significant sialorrhea were randomly assigned to receive a BoNT-A (Dysport(®)) injection into the submandibular and the parotid glands bilaterally via an ultrasound guidance. The total dose given per patient was either BoNT-A injection of (i) 50 U; (ii) 100 U; or (iii) 200 U. The primary outcome was the amount of saliva reduction, measured by the differential weight (wet versus dry) of intraoral dental gauze at baseline and at 2, 6, 12, and 24 weeks after injection. The secondary outcome was the subjective report of drooling using the Drooling Frequency and Severity Scale (DFS). Saliva reduction was observed in response to all BoNT-A doses in 17 patients who completed the assessments. Although no statistically significant difference among the doses was found, the measured reduction was greater in groups that received higher doses (100 U and 200 U). The group receiving 200 U of Dysport(®) showed the greatest reduction of saliva until 24 weeks and reported the most significant improvement in the DFS score. MDPI 2015-09-22 /pmc/articles/PMC4591664/ /pubmed/26402703 http://dx.doi.org/10.3390/toxins7093758 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mazlan, Mazlina Rajasegaran, Shivani Engkasan, Julia Patrick Nawawi, Ouzreiah Goh, Khean-Jin Freddy, Saini Jeffery A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases |
title | A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases |
title_full | A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases |
title_fullStr | A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases |
title_full_unstemmed | A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases |
title_short | A Double-Blind Randomized Controlled Trial Investigating the Most Efficacious Dose of Botulinum Toxin-A for Sialorrhea Treatment in Asian Adults with Neurological Diseases |
title_sort | double-blind randomized controlled trial investigating the most efficacious dose of botulinum toxin-a for sialorrhea treatment in asian adults with neurological diseases |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591664/ https://www.ncbi.nlm.nih.gov/pubmed/26402703 http://dx.doi.org/10.3390/toxins7093758 |
work_keys_str_mv | AT mazlanmazlina adoubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT rajasegaranshivani adoubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT engkasanjuliapatrick adoubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT nawawiouzreiah adoubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT gohkheanjin adoubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT freddysainijeffery adoubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT mazlanmazlina doubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT rajasegaranshivani doubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT engkasanjuliapatrick doubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT nawawiouzreiah doubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT gohkheanjin doubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases AT freddysainijeffery doubleblindrandomizedcontrolledtrialinvestigatingthemostefficaciousdoseofbotulinumtoxinaforsialorrheatreatmentinasianadultswithneurologicaldiseases |